石藥集團(01093.HK)孟魯司特鈉片及咀嚼片獲藥品註冊批件
格隆匯2月25日丨石藥集團(01093.HK)公佈,公司附屬公司石藥集團歐意藥業有限公司開發的孟魯司特鈉片(10mg)及孟魯司特鈉咀嚼片(4mg、5mg)已獲中國國家藥品監督管理局頒發藥品註冊批件,為國內第二家視同通過仿製藥質量和療效一致性評價的品種。
孟魯司特鈉為一種能顯著改善哮喘及過敏性鼻炎症狀的口服制劑,用於哮喘的預防和長期治療,包括預防白天和夜間的哮喘症狀,治療對阿司匹林敏感的哮喘患者以及預防運動誘發的支氣管收縮;以及用於季節性和長年性過敏性鼻炎。孟魯司特鈉片適用於15歲及以上患者,孟魯司特鈉咀嚼片適用於2歲至14歲兒童患者。
該等產品的獲批將進一步豐富集團的產品組合,並能為患者提供優質優價的用藥選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.